Galvani Bioelectronics

Brentford, United Kingdom· Est. 2016

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $715M

Overview

Galvani Bioelectronics, founded in 2016, is a private joint venture between GSK and Verily Life Sciences (Alphabet) focused on developing precision bioelectronic therapies. Its core technology is an implantable, wirelessly controlled neuromodulation platform designed for minimally invasive delivery to treat chronic diseases, starting with immunomodulatory conditions like Rheumatoid Arthritis. The company is currently in the clinical development stage, enrolling patients for its lead RA program, and represents a convergence of biopharma and tech expertise in the emerging field of bioelectronics.

Rheumatoid ArthritisAutoimmune DiseasesImmunologyChronic Inflammatory DiseasesNeurological Disorders

Technology Platform

Implantable, wirelessly controlled neuromodulation platform consisting of an electronics implant, nerve cuff lead, external charger, patient remote, and clinician programmer. Designed for minimally invasive laparoscopic implantation to modulate specific neural signals.

Funding History

Total raised:$715M

Series A$715MGoogleAug 15, 2016

Opportunities

The bioelectronic medicine market is nascent but could disrupt multi-billion dollar chronic disease markets by offering a potentially curative alternative to lifelong drug regimens.

Galvani's platform approach allows for expansion across numerous autoimmune and chronic conditions from a single technological base, offering significant scalability and pipeline value.

Risk Factors

High clinical risk as the novel mechanism of modulating immunity via the splenic nerve is unproven in humans.

Regulatory pathway for a first-in-class implantable device is complex and uncertain.

Commercial adoption faces hurdles from patient/physician reluctance towards surgery and competition from advanced drug therapies.

Competitive Landscape

Galvani's primary competition comes from large pharmaceutical companies with dominant RA drugs (e.g., AbbVie, Pfizer, Amgen) and other bioelectronics firms like SetPoint Medical (vagus nerve stimulation for RA/inflammation), which is also in clinical trials. Galvani is differentiated by its focus on the splenic nerve, its backing by GSK/Verily, and its broader platform ambition.